ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0423

Direct and Indirect Effect of TNFi on BASMI Components in People with Axial Spondyloarthritis: A Longitudinal Study

Ana Pinto1, Claire Harris2, Rhys Hayward2, Andrew Keat2 and Pedro Machado2, 1Local Health Unit of Guarda, Barcelos, Portugal, 2Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom

Meeting: ACR Convergence 2022

Keywords: Biologicals, Outcome measures, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: The Bath Ankylosing Spondylitis Metrology Index (BASMI) is an index of spinal mobility for people with axial spondyloarthritis (axSpA). BASMI is one of the few objective measures of spinal disease progression that does not involve imaging. The assessment of mobility and physical function are essential components of the management of axSpA patients and, with the use of early therapeutics that are effective on improving/preserving function, mobility and, potentially structural damage, understanding the interplay between treatments and the various health outcomes affected by axSpA will contribute to better patient management. Our goal was to describe the long-term effect of TNF inhibitors (TNFi) on spinal mobility (each component of BASMI) in patients with axSpA, and to determine whether the use of TNFi treatment influences spinal mobility and if this is due to a direct or indirect effect (mediated by disease activity).

Methods: We performed a longitudinal study, using data routinely collected from patients with a clinical diagnosis of axSpA treated with TNFi at a specialist tertiary care center. Patients with at least two BASMI measurements (one before and one after TNFi initiation) were included. The relationship between TNFi treatment and BASMI over time was investigated using binomial generalized estimating equations (GEE). GEE is a technique that makes use of all available longitudinal data, allows unequal numbers of repeated measurements, corrects for within-subject correlation, and has some robustness against deviation from normality. We built 5 multivariable models; in the first three we investigated the isolated effect of TNFi (model 1), ASDAS (model 2) and BASDAI+CRP (model 3) on spinal mobility (each BASMI component); then we built two additional models, adjusting simultaneously for TNFi treatment and disease activity – one adjusted for TNFi and ASDAS (model 4) and one adjusted for TNFi and BASDAI+CRP (model 5). Other demographic and clinical variables were included as covariates in all multivariable models, including the time period between starting TNFi and the spinal mobility assessment.

Results: Data from 188 patients and 1326 visits were analysed. Mean age was 45.6 (SD 11.6) years, mean disease duration was 15.8 (SD 9.64) years, 152 (80.9%) were male, 120 (73.6%) had radiographic axSpA, and 83 (74.8%) were HLA-B27 positive. Mean follow-up time was 8.0 (SD 4.4) years, ranging from 0.8 to 18.2 years. In the first three models, we observed a significant effect of TNFi in all the BASMI components, as we did for ASDAS and BASDAI (the only exception being for BASDAI, in the tragus-wall distance model). In the models combining TNFi treatment and disease activity, we found that TNFi treatment was significantly associated with improvement in the majority of BASMI components, even after controlling for disease activity (Table 1).

Conclusion: TNFi has a long-term beneficial effect on all BASMI components, which seems to be both due to an indirect effect (mediated by disease activity) and a direct effect of TNFi treatment.

Supporting image 1

Table 1 – GEE analysis of BASMI items, adjusted for age, gender, bDMARD use, bDMARD duration, Peripheral arthritis, dactylitis, enthesitis, psoriasis, inflammatory bowel disease, uveitis, radiographic axial spondyloarthritis, non-steroid anti-inflammatory drug intake, HLA B27 positivity, BASDAI + CRP or ASDAS


Disclosures: A. Pinto, None; C. Harris, None; R. Hayward, None; A. Keat, None; P. Machado, AbbVie/Abbott, Bristol-Myers Squibb(BMS), Celgene, Eli Lilly, Galapagos, Janssen, Merck/MSD, Orphazyme, Novartis, Pfizer, UCB, Roche.

To cite this abstract in AMA style:

Pinto A, Harris C, Hayward R, Keat A, Machado P. Direct and Indirect Effect of TNFi on BASMI Components in People with Axial Spondyloarthritis: A Longitudinal Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/direct-and-indirect-effect-of-tnfi-on-basmi-components-in-people-with-axial-spondyloarthritis-a-longitudinal-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/direct-and-indirect-effect-of-tnfi-on-basmi-components-in-people-with-axial-spondyloarthritis-a-longitudinal-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology